ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

COMPARISON OF PIOGLITAZONE + METRORMIN VS SITAGLIPTIN + METFORMIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS

Dr. Zahoor Ur Rehman, Dr. Ijaz Ahmad, Dr. Muhammad Aamir Suhail

Objectives: To assess the efficacy of both groups in term of Glycemic control versus comparative side effects. Material and Methods: This Quasi-experimental study is conducted at MTI/Hayatabad Medical Complex Peshawar, from November 2017 to October 2018. Ninety patients of type 2 diabetes mellitus came to OPD, were chosen. In OPD, every patient was analyzed altogether. The restorative alternative was assigned to the patients primarily by utilizing a table of arbitrary numbers and separating them into two equivalent groups. Every patient was pursued on follow up visits (six altogether) and his HbA1c, fasting, and random blood glucose were recorded. Every bit of information along these parameters was handled and examined utilizing SPSS. Mean, and SD was determined for age, BMI, fasting blood glucose, random blood glucose, and HbA1c levels. Results: Mean drop of each of the three parameters were looked at among two groups. Toward the finish of a half year, it was revealed that fasting and arbitrary (2 hours postprandial) blood glucose dropped more in Pioglitazone + Metformin group; P=0.000 and 0.02 separately while the practically equivalent impact was seen in HbA1c (P=0.2). Conclusion: Pioglitazone + Metformin + Sitagliptin + Metformin has a significantly better hypoglycemic effect than Sitagliptin + Sitagliptin + Metformin in type 2 diabetes mellitus at the end of six months of therapy. Keywords: Hypoglycemic, Pioglitazone + Metformin, Sitagliptin + Metformin, Sitagliptin, Diabetes Mellitus, Quasi-Experimental, OPD, BMI, and Blood Glucose.

FULL TEXT